In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.
Search results for: Biologics
Rheuminations: Lessons from 5 Years of COVID-19
My children were playing in the car the other day and pulled open the glove box. Inside, they found a brown paper bag with my last name “KUMAR” in black Sharpie and a red sticker that read, “Do not lose. No replacements available.” It wasn’t long before the kids tore that bag apart to find…
In the Details: Diagnosing PsA Requires Drilling Down
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
ACR Comments on Proposed Medicare Advantage Changes
In response to proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026, the ACR submitted comments on the provisions related to the Inflation Reduction Act, prior authorization and the influence that pharmacy benefit managers have on the placement of biosimilars on formularies.
Precision Medicine on a Population Level
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
Cancer & RA Drugs: Are Some Drugs Riskier than Others?
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
A Look Back at 2024 Regulatory Developments
In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 77
- Next Page »